Navigation Links
Benefits of CyberKnife® Lung Radiosurgery Treatments Emphasized During Europe's Largest Congress in Radiation Oncology
Date:9/17/2010

SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29; the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain. Also featured at this meeting were multiple presentations demonstrating this system's best-in-class motion management capabilities for lung cancer care.

During a well-attended symposium on motion management in lung radiosurgery chaired by Pr. Volker Budach, M.D., Ph.D., Charite – Universitatsmedizin, Berlin, physics and clinical findings were presented by representatives from two CyberKnife sites: Erasmus MC - Daniel den Hoed Cancer Centre in Rotterdam, Netherlands and Centre Antoine Lacassagne in Nice, France. Clinical research presented during the symposium demonstrated the benefits of CyberKnife radiosurgery in the treatment of primary early stage and metastatic lung cancer, including excellent disease control and preservation of quality of life. Enabling these outcomes are the CyberKnife System's unique motion management capabilities including the Synchrony® Respiratory Tracking System, which enables real-time tracking and correction for tumors that move with respiration.

"The Synchrony System is unique in its ability to correct for changes in a patient's pattern of breathing in real-time," said Dr. Joost Nuyttens, M.D., Ph.D., Erasmus MC – Daniel den Hoed Cancer Center, Rotterdam. "This allows us to significantly reduce delivery margins while eliminating the need for abdominal compression or breath-holding techniques."

In addition, two CyberKnife users were recognized for outstanding research. The ACCURAY-ESTRO Award, which for the last several years has recognized radiotherapy professionals for original research in the field of high precision radiotherapy, was awarded to Dr. Joost Nuyttens (Rotterdam), for his lecture entitled "Outcome of Four-dimensional Stereotactic Radiotherapy for centrally located Lung Tumors". Within the National Young Scientist Session, the first prize was won by Jean-Emmanuel Bibault, Resident, Centre Oscar Lambret, Lille for his oral poster reporting on outcomes obtained using the fiducial-free Xsight® Lung Tracking System titled, "Early efficacy and toxicity evaluation of CyberKnife Xsight Lung."

"Both of these awards highlight industry-leading approaches to non-invasive lung cancer treatment using CyberKnife radiosurgery," said Vittorio Puppo, General Manager, Accuray EIMEA (Europe, India, Middle East, Asia). "We congratulate our productive and dedicated users on this fine honor and thank them for their important research contributions."

More than 20 posters and oral presentations during this year's ESTRO meeting highlighted the continued expansion of extracranial radiosurgery applications with the CyberKnife System, including presentations on lung, liver, prostate, spine, pancreas, and head and neck cancer.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 95,000 patients worldwide and currently more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical efficacy, clinical benefits, clinical acceptance, clinical publications, and clinical results are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission on August, 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
2. Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elektas Leksell Gamma Knife Perfexion
3. Riverside Health System Benefits from New Model of Care Facilitation Powered by Curaspan Health Group
4. Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers
5. Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health
6. New Georgia Advanced Surgery Center Provides Women Many Unique Benefits
7. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
8. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
9. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
10. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
11. Benefits from Radiation Therapy Outweigh Risks for Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):